| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Masanori Murakami, Naoko Une, Maiko Nishizawa, Sayaka Suzuki, Hideki Ito, Toshiyuki Horiuch. Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects. SpringerPlus. vol 2. issue 1. 2014-11-18. PMID:23450079. |
we found that udca intake resulted in higher glp-1 secretion (area under the curve [auc] of 0-60 min after meal without udca, 450 ± 162 mmol·min/l; with udca, 649 ± 232 mmol·min/l, p = 0.046) and lower blood glucose (auc of 0-60 min without udca, 7191 ± 250 mg·min/dl; with udca, 6716 ± 189 mg·min/dl, p = 0.001) , although we did not find statistically significant insulin increase by udca intake (auc of 0-60 min without udca, 1551 ± 418 μu·min/ml; with udca, 1941 ± 246 μu·min/ml, p = 0.065). |
2014-11-18 |
2023-08-12 |
human |
| Amanda Jiménez, Andrea Mari, Roser Casamitjana, Antonio Lacy, Ele Ferrannini, Josep Vida. GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes. Diabetes. vol 63. issue 10. 2014-11-18. PMID:24848069. |
in study 2, the blockade of glp-1 action resulted in impaired insulin secretion but limited deterioration of glucose tolerance. |
2014-11-18 |
2023-08-13 |
human |
| Florian Kahles, Christina Meyer, Julia Möllmann, Sebastian Diebold, Hannes M Findeisen, Corinna Lebherz, Christian Trautwein, Alexander Koch, Frank Tacke, Nikolaus Marx, Michael Lehrk. GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes. vol 63. issue 10. 2014-11-18. PMID:24947356. |
the incretine hormone glp-1 was currently found to be induced by endotoxin, leading to insulin secretion and glucose lowering under inflammatory conditions in mice. |
2014-11-18 |
2023-08-13 |
mouse |
| I B Hirsch, J B Buse, J Leahy, J B McGill, A Peters, H W Rodbard, R R Rubin, J S Skyler, C A Verderese, M C Riddl. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Diabetes, obesity & metabolism. vol 16. issue 3. 2014-11-17. PMID:23711193. |
options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting glp-1 analogue versus progression to basal-bolus therapy. |
2014-11-17 |
2023-08-12 |
Not clear |
| I B Hirsch, J B Buse, J Leahy, J B McGill, A Peters, H W Rodbard, R R Rubin, J S Skyler, C A Verderese, M C Riddl. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Diabetes, obesity & metabolism. vol 16. issue 3. 2014-11-17. PMID:23711193. |
this article considers how the addition of a glucagon-like peptide 1 (glp-1) analogue to basal insulin may provide new opportunities at this stage of treatment, especially for patients concerned about weight gain and risk of hypoglycaemia. |
2014-11-17 |
2023-08-12 |
Not clear |
| André J Scheen, Nicolas Paquo. [Potential of a GLP-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes]. Revue medicale suisse. vol 10. issue 439. 2014-11-14. PMID:25272672. |
[potential of a glp-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes]. |
2014-11-14 |
2023-08-13 |
Not clear |
| Annamaria Colao, Christophe De Block, Maria Sonia Gaztambide, Sudhesh Kumar, Jochen Seufert, Felipe F Casanuev. Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. Pituitary. vol 17. issue 2. 2014-11-13. PMID:23564338. |
diabetes mellitus should be managed by initiation of medical therapy with metformin and staged treatment intensification with a dipeptidyl peptidase-4 inhibitor, with a switch to a glp-1 receptor agonist and initiation of insulin, as required, to achieve and maintain glycemic control. |
2014-11-13 |
2023-08-12 |
human |
| Samantha K Li, Dan Zhu, Herbert Y Gaisano, Patricia L Brubake. Role of vesicle-associated membrane protein 2 in exocytosis of glucagon-like peptide-1 from the murine intestinal L cell. Diabetologia. vol 57. issue 4. 2014-11-13. PMID:24356748. |
glucagon-like peptide-1 (glp-1), secreted by the enteroendocrine l cell, is an incretin hormone that potently stimulates insulin secretion. |
2014-11-13 |
2023-08-12 |
Not clear |
| Xiaowei Wei, Xiaowei Ma, Ran Lu, Ge Bai, Jianwei Zhang, Ruifen Deng, Nan Gu, Nan Feng, Xiaohui Gu. Genetic variants in PCSK1 gene are associated with the risk of coronary artery disease in type 2 diabetes in a Chinese Han population: a case control study. PloS one. vol 9. issue 1. 2014-11-08. PMID:24489861. |
insulin and glucagon-like peptide 1 (glp-1), converted by proprotein convertase 1 (pc1/3) from proinsulin and proglucagon, are associated with type 2 diabetes (t2dm) and coronary artery disease (cad). |
2014-11-08 |
2023-08-12 |
Not clear |
| Vo Nguyen Trung, Hiroshi Yamamoto, Tsuyoshi Yamaguchi, Satoshi Murata, Yoshinari Aimi, Atsukazu Kuwahara, Tohru Tan. Intact neural system of the portal vein is important for maintaining normal glucose metabolism by regulating glucagon-like peptide-1 and insulin sensitivity. Peptides. vol 52. 2014-10-31. PMID:24333288. |
one week after surgery, food intake and body weight were monitored; an oral glucose tolerance test (ogtt) was performed; and glucagon-like peptide-1 (glp-1) and insulin levels during ogtt were assayed. |
2014-10-31 |
2023-08-12 |
rat |
| Vo Nguyen Trung, Hiroshi Yamamoto, Tsuyoshi Yamaguchi, Satoshi Murata, Yoshinari Aimi, Atsukazu Kuwahara, Tohru Tan. Intact neural system of the portal vein is important for maintaining normal glucose metabolism by regulating glucagon-like peptide-1 and insulin sensitivity. Peptides. vol 52. 2014-10-31. PMID:24333288. |
dv rats exhibited increased blood glucose levels associated with decreased insulin sensitivity but increased glp-1 and insulin secretion during ogtt. |
2014-10-31 |
2023-08-12 |
rat |
| Ying Li, Mingxiang Shao, Xuemin Zheng, Weiling Kong, Jianning Zhang, Min Gon. Self-assembling peptides improve the stability of glucagon-like peptide-1 by forming a stable and sustained complex. Molecular pharmaceutics. vol 10. issue 9. 2014-10-29. PMID:23859692. |
stabilization, insulin secretion stimulation, and glucose tolerance tests were performed to investigate the physiological characteristics retained by glp-1 following complex formation with self-assembling peptides. |
2014-10-29 |
2023-08-12 |
Not clear |
| S Madsba. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes, obesity & metabolism. vol 16. issue 1. 2014-10-28. PMID:23617798. |
furthermore, glp-1 functions as an incretin hormone, stimulating insulin release and inhibiting glucagon secretion from the pancreas in response to food ingestion. |
2014-10-28 |
2023-08-12 |
human |
| David J Hodson, Ryan K Mitchell, Lorella Marselli, Timothy J Pullen, Silvia Gimeno Brias, Francesca Semplici, Katy L Everett, Dermot M F Cooper, Marco Bugliani, Piero Marchetti, Vanessa Lavallard, Domenico Bosco, Lorenzo Piemonti, Paul R Johnson, Stephen J Hughes, Daliang Li, Wen-Hong Li, A M James Shapiro, Guy A Rutte. ADCY5 couples glucose to insulin secretion in human islets. Diabetes. vol 63. issue 9. 2014-10-28. PMID:24740569. |
next, we demonstrate that adcy5 is indispensable for coupling glucose, but not glp-1, to insulin secretion in human islets. |
2014-10-28 |
2023-08-13 |
human |
| M T Lund, S Dalby, B Hartmann, J Helge, J J Holst, F Del. The incretin effect does not differ in trained and untrained, young, healthy men. Acta physiologica (Oxford, England). vol 210. issue 3. 2014-10-24. PMID:24354574. |
the insulin secretion rate is higher after oral compared with intravenous glucose administration due to the release of glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) enhancing the glucose-induced insulin secretion (the incretin effect). |
2014-10-24 |
2023-08-12 |
Not clear |
| Karianna F M Teunissen-Beekman, Janneke Dopheide, Johanna M Geleijnse, Stephan J L Bakker, Elizabeth J Brink, Peter W de Leeuw, Jan Serroyen, Marleen A van Baa. Differential effects of proteins and carbohydrates on postprandial blood pressure-related responses. The British journal of nutrition. vol 112. issue 4. 2014-10-21. PMID:24893214. |
we hypothesised that lower postprandial total peripheral resistance (tpr) and bp levels would be accompanied by higher plasma concentrations of nitric oxide, insulin, glucagon-like peptide 1 (glp-1) and glucagon. |
2014-10-21 |
2023-08-13 |
Not clear |
| Karianna F M Teunissen-Beekman, Janneke Dopheide, Johanna M Geleijnse, Stephan J L Bakker, Elizabeth J Brink, Peter W de Leeuw, Jan Serroyen, Marleen A van Baa. Differential effects of proteins and carbohydrates on postprandial blood pressure-related responses. The British journal of nutrition. vol 112. issue 4. 2014-10-21. PMID:24893214. |
postprandial responses of tpr, bp and plasma concentrations of insulin, glucagon, glp-1 and nitrite, nitroso compounds (rxno) and s-nitrosothiols (no(x)) were measured for 4 h. no differences were observed in tpr responses. |
2014-10-21 |
2023-08-13 |
Not clear |
| Karianna F M Teunissen-Beekman, Janneke Dopheide, Johanna M Geleijnse, Stephan J L Bakker, Elizabeth J Brink, Peter W de Leeuw, Jan Serroyen, Marleen A van Baa. Differential effects of proteins and carbohydrates on postprandial blood pressure-related responses. The British journal of nutrition. vol 112. issue 4. 2014-10-21. PMID:24893214. |
lower postprandial bp levels are not necessarily accompanied by higher no(x), insulin, glucagon or glp-1 responses. |
2014-10-21 |
2023-08-13 |
Not clear |
| Pia V Röder, Kerstin E Geillinger, Tamara S Zietek, Bernard Thorens, Hermann Koepsell, Hannelore Danie. The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PloS one. vol 9. issue 2. 2014-10-16. PMID:24587162. |
moreover, we examined the contribution of these transporters to glucose-induced changes in plasma gip, glp-1 and insulin levels. |
2014-10-16 |
2023-08-12 |
mouse |
| Alessandra Puddu, Roberta Sanguineti, Fabrizio Montecucco, Giorgio L Vivian. Glucagon-like peptide-1 secreting cell function as well as production of inflammatory reactive oxygen species is differently regulated by glycated serum and high levels of glucose. Mediators of inflammation. vol 2014. 2014-10-16. PMID:24648662. |
here, we aimed at investigating whether diabetic toxic products (glycated serum (gs) or high levels of glucose (hg)) may affect viability, function, and insulin sensitivity of the glp-1 secreting cell line glutag. |
2014-10-16 |
2023-08-12 |
Not clear |